VIDEO: Adding tucatinib to maintenance therapy a ‘great option’ in metastatic breast cancer

SAN ANTONIO — In this video, Eleonora Teplinsky, MD, discusses results of the HER2CLIMB-05 study, showing that adding tucatinib to first-line maintenance therapy improved patient outcomes in HER2-positive metastatic breast cancer.Results of the trial, which compared tucatinib (Tukysa, Seagen) with placebo in combination with trastuzumab (Herceptin, Genentech) and pertuzumab (Perjeta,